Drug class profile · refreshed daily from federal data

Glycopeptide Antibacterial

1 molecule in this class, $75.0M combined CY2024 Part D spend across 571K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Glycopeptide Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
1tracked in Part D
CY24 Part D spend
$75.0Mcombined across class
Total Rx claims
571K273K unique beneficiaries
Generic mfrs (active)
21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Vancomycin
Brand: FIRVANQ · 571K Part D claims (CY24) · 273K beneficiaries · First FDA approval:
21 generic mfrs 55 plans require PA Discontinued
Low NADAC$0.408
Avg plan cost$1.78
Part D spend $75.0M spread, current vs floor
Class share
100%
of class CY24 spend
View profile →